Science Translational Medicine report led by Lymphoma Research Foundation Scientific Advisory Board members and LRF Grantees As personalized medicine becomes increasingly popular, researchers continue to
Read More >
The Annual Meeting of the American Society of Hematology (ASH), convened in December 2014, highlighted the expanding array of novel therapy treatments showing promise for
Read More >
The Annual Meeting of the American Society of Hematology (ASH), convened in December 2014, highlighted the expanding array of novel therapy treatments showing promise for
Read More >
The Annual Meeting of the American Society of Hematology (ASH), convened in December 2014, highlighted the expanding array of novel therapy treatments showing promise for
Read More >In non, eu aliquam mus eu aptent mi justo. Nam nonummy, eget tempor facilisis diam. Et in ut, est dignissim, wisi pellentesque amet est dignissim, in mi vestibulum montes eu nullam.
Read More >Vulputate nonummy molestie. Varius feugiat congue, fringilla sociosqu velit eu justo nullam posuere, ipsum neque at tortor integer, ac vestibulum mauris nullam praesent.
Read More >Cras faucibus vel sed maecenas consectetuer, iaculis montes leo, scelerisque lorem sollicitudin, quis quam condimentum nisl.
Read More >
Though much of the lymphoma research presented at the Annual Meeting of the American Society of Hematology (ASH) in December 2014 focused on the growing
Read More >
Placerat diam luctus orci nec diam mauris, placerat sodales hac nunc risus.
Read More >Double hit lymphoma (DHL) describes patients whose lymphoma tumors exhibit mutations on two significant genes, where most lymphoma patients have a mutation on only one.
Read More >
